GILD250110C50000
- 41.00
- 0.000.00%
Gilead Sciences Newsroom
Gilead Sciences Analyst Ratings
Morgan Stanley Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $113
Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation
RBC Trims Price Target on Gilead Sciences to $83 From $84, Keeps Sector Perform Rating
Gilead Sciences' Buy Rating Affirmed on HIV Market Potential and Strategic Leadership Changes
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Truist Financial Maintains Gilead Sciences(GILD.US) With Hold Rating
Gilead Sciences (GILD) Gets a Hold From Truist Financial
Piper Sandler Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $99 to $115
Gilead Sciences Price Target Maintained With a $80.00/Share by Cantor Fitzgerald
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $84 Price Target
Gilead Sciences Analyst Ratings
Gilead Sciences (GILD) Receives a Buy From Jefferies
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $105 to $125
Gilead Sciences' Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating
Oppenheimer raised the Target Price of Gilead Sciences to $115.
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
Citi Remains a Buy on Gilead Sciences (GILD)